Literature DB >> 22727237

An international model to predict recurrent cardiovascular disease.

Peter W F Wilson1, Ralph D'Agostino, Deepak L Bhatt, Kim Eagle, Michael J Pencina, Sidney C Smith, Mark J Alberts, Jean Dallongeville, Shinya Goto, Alan T Hirsch, Chiau-Suong Liau, E Magnus Ohman, Joachim Röther, Christopher Reid, Jean-Louis Mas, Ph Gabriel Steg.   

Abstract

BACKGROUND: Prediction models for cardiovascular events and cardiovascular death in patients with established cardiovascular disease are not generally available.
METHODS: Participants from the prospective REduction of Atherothrombosis for Continued Health (REACH) Registry provided a global outpatient population with known cardiovascular disease at entry. Cardiovascular prediction models were estimated from the 2-year follow-up data of 49,689 participants from around the world.
RESULTS: A developmental prediction model was estimated from 33,419 randomly selected participants (2394 cardiovascular events with 1029 cardiovascular deaths) from the pool of 49,689. The number of vascular beds with clinical disease, diabetes, smoking, low body mass index, history of atrial fibrillation, cardiac failure, and history of cardiovascular event(s) <1 year before baseline examination increased risk of a subsequent cardiovascular event. Statin (hazard ratio 0.75; 95% confidence interval, 0.69-0.82) and acetylsalicylic acid therapy (hazard ratio 0.90; 95% confidence interval, 0.83-0.99) also were significantly associated with reduced risk of cardiovascular events. The prediction model was validated in the remaining 16,270 REACH subjects (1172 cardiovascular events, 494 cardiovascular deaths). Risk of cardiovascular death was similarly estimated with the same set of risk factors. Simple algorithms were developed for prediction of overall cardiovascular events and for cardiovascular death.
CONCLUSIONS: This study establishes and validates a risk model to predict secondary cardiovascular events and cardiovascular death in outpatients with established atherothrombotic disease. Traditional risk factors, burden of disease, lack of treatment, and geographic location all are related to an increased risk of subsequent cardiovascular morbidity and cardiovascular mortality.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22727237     DOI: 10.1016/j.amjmed.2012.01.014

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  55 in total

1.  Prevalence of Pragmatically Defined High CV Risk and its Correlates in LMIC: A Report From 10 LMIC Areas in Africa, Asia, and South America.

Authors:  Rodrigo M Carrillo-Larco; J Jaime Miranda; Xian Li; Chendi Cui; Xiaolin Xu; Mohammed Ali; Dewan S Alam; Thomas A Gaziano; Rajeev Gupta; Vilma Irazola; Naomi S Levitt; Dorairaj Prabhakaran; Adolfo Rubinstein; Krisela Steyn; Nikhil Tandon; Denis Xavier; Yangfeng Wu; Lijing L Yan
Journal:  Glob Heart       Date:  2016-03

2.  Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.

Authors:  Emmanuel Sorbets; Julien Labreuche; Tabassome Simon; Laurent Delorme; Nicolas Danchin; Pierre Amarenco; Shinya Goto; Christophe Meune; Kim A Eagle; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Eur Heart J       Date:  2014-03-09       Impact factor: 29.983

3.  Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry.

Authors:  Jérémie Abtan; Deepak L Bhatt; Yedid Elbez; Emmanuel Sorbets; Kim Eagle; Yasuo Ikeda; David Wu; Mary E Hanson; Hakima Hannachi; Puneet K Singhal; Philippe Gabriel Steg; Gregory Ducrocq
Journal:  Clin Cardiol       Date:  2016-09-02       Impact factor: 2.882

Review 4.  Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Christopher Carroll; Paul Tappenden; Rachid Rafia; Jean Hamilton; Duncan Chambers; Mark Clowes; Paul Durrington; Nadeem Qureshi; Anthony S Wierzbicki
Journal:  Pharmacoeconomics       Date:  2017-05       Impact factor: 4.981

5.  Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.

Authors:  Gregg C Fonarow; Anthony C Keech; Terje R Pedersen; Robert P Giugliano; Peter S Sever; Peter Lindgren; Ben van Hout; Guillermo Villa; Yi Qian; Ransi Somaratne; Marc S Sabatine
Journal:  JAMA Cardiol       Date:  2017-10-01       Impact factor: 14.676

Review 6.  The myth of 'stable' coronary artery disease.

Authors:  Keith A A Fox; Marco Metra; João Morais; Dan Atar
Journal:  Nat Rev Cardiol       Date:  2019-07-29       Impact factor: 32.419

Review 7.  Beta-Blockers, Calcium Channel Blockers, and Mortality in Stable Coronary Artery Disease.

Authors:  Jose B Cruz Rodriguez; Haider Alkhateeb
Journal:  Curr Cardiol Rep       Date:  2020-01-29       Impact factor: 2.931

8.  Relevance of stroke subtype in vascular risk prediction.

Authors:  Angel Ois; Elisa Cuadrado-Godia; Ana Rodríguez-Campello; Eva Giralt-Steinhauer; Jordi Jiménez-Conde; Miguel Lopez-Cuiña; Miguel Ley; Carol Soriano; Jaume Roquer
Journal:  Neurology       Date:  2013-07-03       Impact factor: 9.910

9.  The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.

Authors:  Tracey G Simon; Kathleen E Corey; Christopher P Cannon; Michael Blazing; Jeong-Gun Park; Michelle L O'Donoghue; Raymond T Chung; Robert P Giugliano
Journal:  Int J Cardiol       Date:  2018-05-26       Impact factor: 4.164

10.  Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease.

Authors:  Michele Massimo Gulizia; Furio Colivicchi; Maurizio Giuseppe Abrignani; Marco Ambrosetti; Nadia Aspromonte; Gabriella Barile; Roberto Caporale; Giancarlo Casolo; Emilia Chiuini; Andrea Di Lenarda; Pompilio Faggiano; Domenico Gabrielli; Giovanna Geraci; Alessio Gaetano La Manna; Aldo Pietro Maggioni; Alfredo Marchese; Ferdinando Maria Massari; Gian Francesco Mureddu; Giuseppe Musumeci; Federico Nardi; Antonio Vittorio Panno; Roberto Franco Enrico Pedretti; Massimo Piredda; Enrico Pusineri; Carmine Riccio; Roberta Rossini; Fortunato Scotto di Uccio; Stefano Urbinati; Ferdinando Varbella; Giovanni Battista Zito; Leonardo De Luca
Journal:  Eur Heart J Suppl       Date:  2018-05-31       Impact factor: 1.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.